Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

YAAS vs CANG vs AUTL vs BZUN

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
YAAS
Youxin Technology Ltd

Software - Application

TechnologyNASDAQ • CN
Market Cap$419K
5Y Perf.-99.7%
CANG
Cango Inc.

Auto - Dealerships

Consumer CyclicalNYSE • CN
Market Cap$250M
5Y Perf.-75.6%
AUTL
Autolus Therapeutics plc

Biotechnology

HealthcareNASDAQ • GB
Market Cap$410M
5Y Perf.-31.7%
BZUN
Baozun Inc.

Specialty Retail

Consumer CyclicalNASDAQ • CN
Market Cap$165M
5Y Perf.+1.5%

YAAS vs CANG vs AUTL vs BZUN — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
YAAS logoYAAS
CANG logoCANG
AUTL logoAUTL
BZUN logoBZUN
IndustrySoftware - ApplicationAuto - DealershipsBiotechnologySpecialty Retail
Market Cap$419K$250M$410M$165M
Revenue (TTM)$1M$3.46B$51M$9.77B
Net Income (TTM)$-4M$-178M$-225M$-204M
Gross Margin57.2%13.6%-309.4%49.2%
Operating Margin-248.7%7.3%-8.6%-0.5%
Forward P/E5.7x1.0x
Total Debt$2M$170M$53M$2.52B
Cash & Equiv.$18K$1.29B$227M$1.64B

YAAS vs CANG vs AUTL vs BZUNLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

YAAS
CANG
AUTL
BZUN
StockDec 24May 26Return
Youxin Technology L… (YAAS)1000.3-99.7%
Cango Inc. (CANG)10024.4-75.6%
Autolus Therapeutic… (AUTL)10068.3-31.7%
Baozun Inc. (BZUN)100101.5+1.5%

Price return only. Dividends and distributions are not included.

Quick Verdict: YAAS vs CANG vs AUTL vs BZUN

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: BZUN leads in 5 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Autolus Therapeutics plc is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
YAAS
Youxin Technology Ltd
The Specific-Use Pick

YAAS plays a supporting role in this comparison — it may shine differently against other peers.

Best for: technology exposure
CANG
Cango Inc.
The Long-Run Compounder

CANG is the clearest fit if your priority is long-term compounding.

  • -44.9% 10Y total return vs BZUN's -49.3%
Best for: long-term compounding
AUTL
Autolus Therapeutics plc
The Growth Play

AUTL is the #2 pick in this set and the best alternative if growth exposure is your priority.

  • Rev growth 496.0%, EPS growth 27.5%, 3Y rev CAGR 88.7%
  • 496.0% revenue growth vs CANG's -52.7%
  • +30.5% vs YAAS's -99.2%
Best for: growth exposure
BZUN
Baozun Inc.
The Income Pick

BZUN carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.

  • Dividend streak 0 yrs, beta 1.48, yield 0.1%
  • Lower volatility, beta 1.48, Low D/E 43.6%, current ratio 1.93x
  • Beta 1.48, yield 0.1%, current ratio 1.93x
  • Better valuation composite
Best for: income & stability and sleep-well-at-night
See the full category breakdown
CategoryWinnerWhy
GrowthAUTL logoAUTL496.0% revenue growth vs CANG's -52.7%
ValueBZUN logoBZUNBetter valuation composite
Quality / MarginsBZUN logoBZUN-2.1% margin vs AUTL's -439.7%
Stability / SafetyBZUN logoBZUNBeta 1.48 vs CANG's 2.25
DividendsBZUN logoBZUN0.1% yield; the other 3 pay no meaningful dividend
Momentum (1Y)AUTL logoAUTL+30.5% vs YAAS's -99.2%
Efficiency (ROA)BZUN logoBZUN-2.1% ROA vs YAAS's -65.8%

YAAS vs CANG vs AUTL vs BZUN — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

YAASYouxin Technology Ltd

Segment breakdown not available.

CANGCango Inc.
FY 2024
After-market Service Facilitation Service Income
62.9%$41M
Loan Facilitation Income And Other Related Income
24.1%$16M
Automobile trading income
9.6%$6M
Service, Other
3.4%$2M
AUTLAutolus Therapeutics plc
FY 2024
License
100.0%$10M
BZUNBaozun Inc.
FY 2024
Service
63.2%$6.0B
Product
36.8%$3.5B

YAAS vs CANG vs AUTL vs BZUN — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLCANGLAGGINGAUTL

Income & Cash Flow (Last 12 Months)

CANG leads this category, winning 3 of 6 comparable metrics.

BZUN is the larger business by revenue, generating $9.8B annually — 7202.3x YAAS's $1M. Profitability is closely matched — net margins range from -2.1% (BZUN) to -4.4% (AUTL). On growth, CANG holds the edge at +58.3% YoY revenue growth, suggesting stronger near-term business momentum.

MetricYAAS logoYAASYouxin Technology…CANG logoCANGCango Inc.AUTL logoAUTLAutolus Therapeut…BZUN logoBZUNBaozun Inc.
RevenueTrailing 12 months$1M$3.5B$51M$9.8B
EBITDAEarnings before interest/tax-$3M$333M-$427M-$4M
Net IncomeAfter-tax profit-$4M-$178M-$225M-$204M
Free Cash FlowCash after capex-$4M$0-$278M$0
Gross MarginGross profit ÷ Revenue+57.2%+13.6%-3.1%+49.2%
Operating MarginEBIT ÷ Revenue-2.5%+7.3%-8.6%-0.5%
Net MarginNet income ÷ Revenue-2.7%-5.2%-4.4%-2.1%
FCF MarginFCF ÷ Revenue-2.8%-154.0%-5.4%-1.1%
Rev. Growth (YoY)Latest quarter vs prior year+21.2%+58.3%+4.8%
EPS Growth (YoY)Latest quarter vs prior year+97.8%+3.6%+3.2%-29.2%
CANG leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

BZUN leads this category, winning 3 of 4 comparable metrics.

On an enterprise value basis, CANG's 3.1x EV/EBITDA is more attractive than BZUN's 15.4x.

MetricYAAS logoYAASYouxin Technology…CANG logoCANGCango Inc.AUTL logoAUTLAutolus Therapeut…BZUN logoBZUNBaozun Inc.
Market CapShares × price$419,114$250M$410M$165M
Enterprise ValueMkt cap + debt − cash$2M$85M$235M$294M
Trailing P/EPrice ÷ TTM EPS-0.33x5.66x-1.84x-6.08x
Forward P/EPrice ÷ next-FY EPS est.0.95x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple3.13x15.40x
Price / SalesMarket cap ÷ Revenue0.80x2.12x40.47x0.12x
Price / BookPrice ÷ Book value/share0.42x0.96x0.19x
Price / FCFMarket cap ÷ FCF
BZUN leads this category, winning 3 of 4 comparable metrics.

Profitability & Efficiency

Evenly matched — CANG and BZUN each lead in 4 of 9 comparable metrics.

BZUN delivers a -3.7% return on equity — every $100 of shareholder capital generates $-4 in annual profit, vs $-109 for YAAS. CANG carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to BZUN's 0.44x. On the Piotroski fundamental quality scale (0–9), BZUN scores 6/9 vs YAAS's 2/9, reflecting solid financial health.

MetricYAAS logoYAASYouxin Technology…CANG logoCANGCango Inc.AUTL logoAUTLAutolus Therapeut…BZUN logoBZUNBaozun Inc.
ROE (TTM)Return on equity-109.2%-4.1%-84.7%-3.7%
ROA (TTM)Return on assets-65.8%-2.3%-34.0%-2.1%
ROICReturn on invested capital+4.6%-2.0%-1.3%
ROCEReturn on capital employed+4.5%-45.9%-1.7%
Piotroski ScoreFundamental quality 0–92456
Debt / EquityFinancial leverage0.04x0.12x0.44x
Net DebtTotal debt minus cash$1M-$1.1B-$175M$879M
Cash & Equiv.Liquid assets$18,372$1.3B$227M$1.6B
Total DebtShort + long-term debt$2M$170M$53M$2.5B
Interest CoverageEBIT ÷ Interest expense-1.87x-25.98x-0.78x
Evenly matched — CANG and BZUN each lead in 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

CANG leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in CANG five years ago would be worth $8,579 today (with dividends reinvested), compared to $34 for YAAS. Over the past 12 months, AUTL leads with a +30.5% total return vs YAAS's -99.2%. The 3-year compound annual growth rate (CAGR) favors CANG at 0.4% vs YAAS's -85.0% — a key indicator of consistent wealth creation.

MetricYAAS logoYAASYouxin Technology…CANG logoCANGCango Inc.AUTL logoAUTLAutolus Therapeut…BZUN logoBZUNBaozun Inc.
YTD ReturnYear-to-date-34.4%-62.0%-14.2%-1.8%
1-Year ReturnPast 12 months-99.2%-73.7%+30.5%-15.9%
3-Year ReturnCumulative with dividends-99.7%+1.2%-14.6%-40.4%
5-Year ReturnCumulative with dividends-99.7%-14.2%-70.1%-91.6%
10-Year ReturnCumulative with dividends-99.7%-44.9%-93.6%-49.3%
CAGR (3Y)Annualised 3-year return-85.0%+0.4%-5.1%-15.8%
CANG leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — AUTL and BZUN each lead in 1 of 2 comparable metrics.

BZUN is the less volatile stock with a 1.48 beta — it tends to amplify market swings less than CANG's 2.25 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AUTL currently trades 59.4% from its 52-week high vs YAAS's 0.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricYAAS logoYAASYouxin Technology…CANG logoCANGCango Inc.AUTL logoAUTLAutolus Therapeut…BZUN logoBZUNBaozun Inc.
Beta (5Y)Sensitivity to S&P 5001.60x2.25x1.95x1.48x
52-Week HighHighest price in past year$560.00$2.88$2.70$4.88
52-Week LowLowest price in past year$0.75$0.33$1.15$2.07
% of 52W HighCurrent price vs 52-week peak+0.2%+18.6%+59.4%+56.6%
RSI (14)Momentum oscillator 0–10049.758.664.353.8
Avg Volume (50D)Average daily shares traded3.6M1.3M1.6M376K
Evenly matched — AUTL and BZUN each lead in 1 of 2 comparable metrics.

Analyst Outlook

CANG leads this category, winning 1 of 1 comparable metric.

Analyst consensus: CANG as "Buy", AUTL as "Buy", BZUN as "Buy". Consensus price targets imply 459.2% upside for CANG (target: $3) vs 93.8% for BZUN (target: $5).

MetricYAAS logoYAASYouxin Technology…CANG logoCANGCango Inc.AUTL logoAUTLAutolus Therapeut…BZUN logoBZUNBaozun Inc.
Analyst RatingConsensus buy/hold/sellBuyBuyBuy
Price TargetConsensus 12-month target$3.00$8.87$5.35
# AnalystsCovering analysts21413
Dividend YieldAnnual dividend ÷ price+0.1%
Dividend StreakConsecutive years of raises50
Dividend / ShareAnnual DPS$0.02
Buyback YieldShare repurchases ÷ mkt cap0.0%+5.3%0.0%+8.5%
CANG leads this category, winning 1 of 1 comparable metric.
Key Takeaway

CANG leads in 3 of 6 categories (Income & Cash Flow, Total Returns). BZUN leads in 1 (Valuation Metrics). 2 tied.

Best OverallCango Inc. (CANG)Leads 3 of 6 categories
Loading custom metrics...

YAAS vs CANG vs AUTL vs BZUN: Key Questions Answered

9 questions · data-driven answers · updated daily

01

Is YAAS or CANG or AUTL or BZUN a better buy right now?

For growth investors, Autolus Therapeutics plc (AUTL) is the stronger pick with 496.

0% revenue growth year-over-year, versus -52. 7% for Cango Inc. (CANG). Cango Inc. (CANG) offers the better valuation at 5. 7x trailing P/E, making it the more compelling value choice. Analysts rate Cango Inc. (CANG) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — YAAS or CANG or AUTL or BZUN?

Over the past 5 years, Cango Inc.

(CANG) delivered a total return of -14. 2%, compared to -99. 7% for Youxin Technology Ltd (YAAS). Over 10 years, the gap is even starker: CANG returned -44. 9% versus YAAS's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — YAAS or CANG or AUTL or BZUN?

By beta (market sensitivity over 5 years), Baozun Inc.

(BZUN) is the lower-risk stock at 1. 48β versus Cango Inc. 's 2. 25β — meaning CANG is approximately 52% more volatile than BZUN relative to the S&P 500. On balance sheet safety, Cango Inc. (CANG) carries a lower debt/equity ratio of 4% versus 44% for Baozun Inc. — giving it more financial flexibility in a downturn.

04

Which is growing faster — YAAS or CANG or AUTL or BZUN?

By revenue growth (latest reported year), Autolus Therapeutics plc (AUTL) is pulling ahead at 496.

0% versus -52. 7% for Cango Inc. (CANG). On earnings-per-share growth, the picture is similar: Cango Inc. grew EPS 960. 0% year-over-year, compared to 27. 5% for Autolus Therapeutics plc. Over a 3-year CAGR, AUTL leads at 88. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — YAAS or CANG or AUTL or BZUN?

Cango Inc.

(CANG) is the more profitable company, earning 37. 3% net margin versus -21. 8% for Autolus Therapeutics plc — meaning it keeps 37. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CANG leads at 22. 2% versus -23. 9% for AUTL. At the gross margin level — before operating expenses — YAAS leads at 65. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Is YAAS or CANG or AUTL or BZUN more undervalued right now?

Analyst consensus price targets imply the most upside for CANG: 459.

2% to $3. 00.

07

Which pays a better dividend — YAAS or CANG or AUTL or BZUN?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

08

Is YAAS or CANG or AUTL or BZUN better for a retirement portfolio?

For long-horizon retirement investors, Baozun Inc.

(BZUN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Cango Inc. (CANG) carries a higher beta of 2. 25 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BZUN: -49. 3%, CANG: -44. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

09

What are the main differences between YAAS and CANG and AUTL and BZUN?

These companies operate in different sectors (YAAS (Technology) and CANG (Consumer Cyclical) and AUTL (Healthcare) and BZUN (Consumer Cyclical)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: YAAS is a small-cap quality compounder stock; CANG is a small-cap deep-value stock; AUTL is a small-cap high-growth stock; BZUN is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

YAAS

High-Growth Disruptor

  • Sector: Technology
  • Market Cap > $20B
  • Revenue Growth > 10%
  • Gross Margin > 34%
Run This Screen
Stocks Like

CANG

High-Growth Disruptor

  • Sector: Consumer Cyclical
  • Market Cap > $100B
  • Revenue Growth > 2916%
Run This Screen
Stocks Like

AUTL

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 247%
Run This Screen
Stocks Like

BZUN

Quality Business

  • Sector: Consumer Cyclical
  • Market Cap > $100B
  • Gross Margin > 29%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform YAAS and CANG and AUTL and BZUN on the metrics below

Revenue Growth>
%
(YAAS: 21.2% · CANG: 5833.4%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.